FIELD: biotechnology.
SUBSTANCE: invention relates to production of immunocytokine capable of specific binding to human PD-L1 antigen and inhibition of PD-L1 binding with PD-1. Obtained immunocytokine contains human cytokine IL-2, as well as heavy and light chains of immunoglobulin, where the heavy chain contains CDRH1 with SEQ ID NO: 27 or SEQ ID NO: 30, CDRH2 with SEQ ID NO: 28 or SEQ ID NO: 31 and CDRH3 with SEQ ID NO: 29 or SEQ ID NO: 32, and light chain contains CDRL1 c SEQ ID NO: 37 or SEQ ID NO: 40; CDRL2 with SEQ ID NO: 38, SEQ ID NO: 41 or SEQ ID NO: 50; and CDRL3 with SEQ ID NO: 39 or SEQ ID NO: 42.
EFFECT: obtained immunocytokine can be used for effective treatment of mediated hPD-L1 disease.
36 cl, 37 dwg, 22 tbl, 31 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| MOLECULES BINDING TO 4-1BB | 2011 |
|
RU2551963C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| ANTIBODIES SPECIFIC TO MMP9 | 2015 |
|
RU2714043C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| CD40L ANTIBODIES AND METHODS OF TREATING CD40L RELATED DISEASES AND DISORDERS | 2016 |
|
RU2727646C2 |
